Oncotype DX and Prosigna in breast cancer patients: A comparison study
Background: Oncotype Dx® (ODX) is the most used prognostic and predictive assay for ER + breast cancer (BCa) and is categorized into low (< 18), intermediate (18 to 30), or high (≥31) risk of recurrence. Prosigna® is a prognostic signature to estimate distant recurrence-free survival for stage I/II,...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2021-01-01
|
| coleção: | Cancer Treatment and Research Communications |
| Assuntos: | |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S2468294221000058 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|